Want to see SE:SUBGEN full AI Analyst Report?
Top Page
AegirBio AB
(SUBGEN)
Select Model
Select Model
Rating:41Neutral
Price Target:
kr0.03
Action:Reiterated
Date:08/28/26
The score is held down primarily by weak financial performance—very large operating and net losses and still-negative free cash flow—despite strong revenue growth and improved operating cash flow. Technicals further pressure the score, with the stock in a clear downtrend (below major moving averages and negative MACD). Valuation contributes limited support because the company is unprofitable (negative P/E) and no dividend yield is provided.
Positive Factors
Strong Revenue Growth
The sharp increase in TTM revenue indicates improving commercial traction and expanding business scale. If this growth continues, it could provide operating leverage and strengthen the company’s ability to support product development, customer adoption, and eventual profitability.
Negative Factors
Severe and Persistent Losses
Very large operating and net losses show that revenue growth has not yet translated into a sustainable earnings model. Continued losses can consume equity, limit reinvestment capacity, and make the company increasingly dependent on additional funding to maintain operations and growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
The sharp increase in TTM revenue indicates improving commercial traction and expanding business scale. If this growth continues, it could provide operating leverage and strengthen the company’s ability to support product development, customer adoption, and eventual profitability.
Read all positive factors
AegirBio AB (SUBGEN) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr64.99M
Dividend YieldN/A
Average Volume (3M)27.29M
Price to Earnings (P/E)―
Beta (1Y)5.67
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees251
SectorTechnology
Sector Strength88
IndustrySoftware - Infrastructure
Share Statistics
EPS (TTM)-0.11
Shares Outstanding1,482,451,200
10 Day Avg. Volume17,385,577
30 Day Avg. Volume27,285,131
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00073
P/FCF Ratio>-0.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
AegirBio AB Business Overview & Revenue Model
Company Description
Subgen AI AB develops artificial intelligence-based models and applications to control data for government and businesses. The company engages in the provision of information society services aimed at delivering financial and related knowledge too...
How the Company Makes Money
Publicly verifiable, up-to-date detail on AegirBio AB’s specific revenue model (e.g., current product portfolio sold, pricing structure, customer mix, revenue breakdown by segment/geography, and named commercial partnerships) is not available in t...
AegirBio AB Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
45
Neutral
Cash Flow
34
Negative
| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 215.49M | 204.39M | 203.76M | 92.00K | 1.71M | 13.28M |
| Gross Profit | 74.27M | 75.16M | -14.27M | 44.00K | -23.71M | 5.51M |
| EBITDA | -134.75M | -104.63M | -27.02M | -34.67M | -351.78M | -74.20M |
| Net Income | -121.30M | -88.88M | -49.63M | -59.70M | -362.83M | -92.33M |
Balance Sheet | ||||||
| Total Assets | 808.26M | 617.77M | 32.61M | 53.10M | 66.87M | 404.37M |
| Cash, Cash Equivalents and Short-Term Investments | 19.51M | 18.74M | 283.00K | 12.14M | 14.59M | 34.03M |
| Total Debt | 240.41M | 102.41M | 45.48M | 32.72M | 7.58M | 9.83M |
| Total Liabilities | 345.68M | 200.62M | 71.25M | 54.55M | 27.04M | 33.95M |
| Stockholders Equity | 462.59M | 418.65M | -38.65M | -1.45M | 39.83M | 370.42M |
Cash Flow | ||||||
| Free Cash Flow | -6.84M | -20.59M | -12.58M | -47.52M | -49.06M | -109.37M |
| Operating Cash Flow | 17.59M | -12.56M | -12.57M | -41.99M | -49.00M | -109.37M |
| Investing Cash Flow | -32.55M | -66.47M | -15.55M | -5.54M | -65.00K | 1.60M |
| Financing Cash Flow | 33.10M | 89.26M | 16.24M | 45.05M | 29.26M | 130.25M |
AegirBio AB Technical Analysis
Negative
―
Price Trends
0.05
Negative
0.07
Negative
0.47
Negative
Market Momentum
>-0.01
Negative
32.30
Neutral
21.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SUBGEN, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 0.04, equal to the 50-day MA of 0.05, and equal to the 200-day MA of 0.47, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 32.30 is Neutral, neither overbought nor oversold. The STOCH value of 21.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SUBGEN.
AegirBio AB Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
83 Outperform | kr485.53M | 15.37 | ― | 4.41% | 6.76% | 1.88% | |
65 Neutral | kr1.79B | 42.09 | ― | 15.83% | ― | ― | |
62 Neutral | kr466.38M | 18.68 | 36.23% | 2.35% | -15.03% | -60.80% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
49 Neutral | kr16.95M | -0.39 | ― | ― | -18.34% | 59.68% | |
44 Neutral | kr2.07B | -15.12 | ― | ― | 35.21% | 40.30% | |
41 Neutral | kr64.99M | -0.29 | -27.63% | ― | ― | ― |
* Technology Sector Average
SE:SUBGEN
AegirBio AB
0.03
-10.57
-99.70%
SE:SLEEP
Sleep Cycle AB
22.60
-1.56
-6.46%
SE:QCORE
Qlucore AB
0.40
-0.17
-30.70%
SE:GENI
Generic Sweden AB
39.65
-8.81
-18.18%
SE:CARA
Carasent AB
26.20
0.35
1.35%
SE:SEYE
Smart Eye AB
51.55
-30.15
-36.90%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.